Browsing Tag
NLRP3
3 posts
Insilico Medicine, Hygtia Therapeutics to advance AI-designed NLRP3 inhibitor for CNS diseases
Insilico and Hygtia partner to advance ISM8969, a brain-penetrant AI-designed NLRP3 inhibitor for CNS diseases. Find out what this means for the field.
Neumora (NASDAQ: NMRA) to begin Phase 1 trial of oral NLRP3 obesity pill in early 2026: Can it rival GLP-1 pills?
Find out how Neumora Therapeutics’ oral obesity candidate NMRA‑215 is advancing to human trials. Could it reshape the future of weight loss therapies?
Ventyx Biosciences announces positive Phase 2 trial data for VTX3232 in obesity and cardiometabolic risk
Find out how Ventyx Biosciences’ VTX3232 is reshaping the obesity and cardiometabolic space through inflammation-targeted innovation.